Logo image of ADN1.DE

ADESSO SE (ADN1.DE) Stock Fundamental Analysis

Europe - Frankfurt Stock Exchange - FRA:ADN1 - DE000A0Z23Q5 - Common Stock

92 EUR
-0.2 (-0.22%)
Last: 12/4/2025, 5:26:53 PM
Fundamental Rating

5

ADN1 gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 72 industry peers in the IT Services industry. ADN1 has only an average score on both its financial health and profitability. ADN1 is not priced too expensively while it is growing strongly. Keep and eye on this one!


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

ADN1 had positive earnings in the past year.
ADN1 had a positive operating cash flow in the past year.
In the past 5 years ADN1 has always been profitable.
ADN1 had a positive operating cash flow in each of the past 5 years.
ADN1.DE Yearly Net Income VS EBIT VS OCF VS FCFADN1.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

1.2 Ratios

With a Return On Assets value of 2.45%, ADN1 is not doing good in the industry: 62.50% of the companies in the same industry are doing better.
ADN1 has a Return On Equity (10.90%) which is in line with its industry peers.
ADN1's Return On Invested Capital of 5.23% is on the low side compared to the rest of the industry. ADN1 is outperformed by 66.67% of its industry peers.
The Average Return On Invested Capital over the past 3 years for ADN1 is significantly below the industry average of 27.45%.
The 3 year average ROIC (3.16%) for ADN1 is below the current ROIC(5.23%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 2.45%
ROE 10.9%
ROIC 5.23%
ROA(3y)1.93%
ROA(5y)3.99%
ROE(3y)6.49%
ROE(5y)13.12%
ROIC(3y)3.16%
ROIC(5y)4.51%
ADN1.DE Yearly ROA, ROE, ROICADN1.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5 10 15 20 25

1.3 Margins

ADN1 has a worse Profit Margin (0.99%) than 65.28% of its industry peers.
ADN1's Profit Margin has declined in the last couple of years.
ADN1's Operating Margin of 2.96% is on the low side compared to the rest of the industry. ADN1 is outperformed by 69.44% of its industry peers.
In the last couple of years the Operating Margin of ADN1 has declined.
ADN1's Gross Margin of 85.30% is fine compared to the rest of the industry. ADN1 outperforms 76.39% of its industry peers.
In the last couple of years the Gross Margin of ADN1 has remained more or less at the same level.
Industry RankSector Rank
OM 2.96%
PM (TTM) 0.99%
GM 85.3%
OM growth 3Y-30%
OM growth 5Y-15.03%
PM growth 3Y-55.28%
PM growth 5Y-30.54%
GM growth 3Y-0.02%
GM growth 5Y-0.7%
ADN1.DE Yearly Profit, Operating, Gross MarginsADN1.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80

4

2. Health

2.1 Basic Checks

ADN1 has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, ADN1 has less shares outstanding
Compared to 5 years ago, ADN1 has more shares outstanding
ADN1 has a better debt/assets ratio than last year.
ADN1.DE Yearly Shares OutstandingADN1.DE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M
ADN1.DE Yearly Total Debt VS Total AssetsADN1.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

An Altman-Z score of 3.65 indicates that ADN1 is not in any danger for bankruptcy at the moment.
ADN1's Altman-Z score of 3.65 is amongst the best of the industry. ADN1 outperforms 81.94% of its industry peers.
ADN1 has a debt to FCF ratio of 7.88. This is a slightly negative value and a sign of low solvency as ADN1 would need 7.88 years to pay back of all of its debts.
With a Debt to FCF ratio value of 7.88, ADN1 is not doing good in the industry: 70.83% of the companies in the same industry are doing better.
A Debt/Equity ratio of 1.60 is on the high side and indicates that ADN1 has dependencies on debt financing.
ADN1 has a worse Debt to Equity ratio (1.60) than 79.17% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.6
Debt/FCF 7.88
Altman-Z 3.65
ROIC/WACC0.51
WACC10.29%
ADN1.DE Yearly LT Debt VS Equity VS FCFADN1.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.3 Liquidity

ADN1 has a Current Ratio of 1.30. This is a normal value and indicates that ADN1 is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of ADN1 (1.30) is comparable to the rest of the industry.
ADN1 has a Quick Ratio of 1.30. This is a normal value and indicates that ADN1 is financially healthy and should not expect problems in meeting its short term obligations.
With a decent Quick ratio value of 1.30, ADN1 is doing good in the industry, outperforming 65.28% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.3
Quick Ratio 1.3
ADN1.DE Yearly Current Assets VS Current LiabilitesADN1.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

8

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 200.98% over the past year.
Measured over the past years, ADN1 shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -15.02% on average per year.
ADN1 shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 12.60%.
Measured over the past years, ADN1 shows a very strong growth in Revenue. The Revenue has been growing by 23.60% on average per year.
EPS 1Y (TTM)200.98%
EPS 3Y-45.14%
EPS 5Y-15.02%
EPS Q2Q%9.8%
Revenue 1Y (TTM)12.6%
Revenue growth 3Y24.12%
Revenue growth 5Y23.6%
Sales Q2Q%13.44%

3.2 Future

Based on estimates for the next years, ADN1 will show a very strong growth in Earnings Per Share. The EPS will grow by 39.75% on average per year.
ADN1 is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.61% yearly.
EPS Next Y105.03%
EPS Next 2Y80.21%
EPS Next 3Y64.94%
EPS Next 5Y39.75%
Revenue Next Year10.46%
Revenue Next 2Y10.44%
Revenue Next 3Y10.29%
Revenue Next 5Y10.61%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ADN1.DE Yearly Revenue VS EstimatesADN1.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B 2B 2.5B
ADN1.DE Yearly EPS VS EstimatesADN1.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 5 10

5

4. Valuation

4.1 Price/Earnings Ratio

ADN1 is valuated quite expensively with a Price/Earnings ratio of 28.84.
Based on the Price/Earnings ratio, ADN1 is valued a bit more expensive than 61.11% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.37, ADN1 is valued at the same level.
With a Price/Forward Earnings ratio of 15.53, ADN1 is valued correctly.
ADN1's Price/Forward Earnings ratio is in line with the industry average.
Compared to an average S&P500 Price/Forward Earnings ratio of 36.20, ADN1 is valued rather cheaply.
Industry RankSector Rank
PE 28.84
Fwd PE 15.53
ADN1.DE Price Earnings VS Forward Price EarningsADN1.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ADN1 indicates a somewhat cheap valuation: ADN1 is cheaper than 65.28% of the companies listed in the same industry.
ADN1's Price/Free Cash Flow is on the same level as the industry average.
Industry RankSector Rank
P/FCF 12.85
EV/EBITDA 6.78
ADN1.DE Per share dataADN1.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 100 200 300

4.3 Compensation for Growth

ADN1's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
ADN1's earnings are expected to grow with 64.94% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.27
PEG (5Y)N/A
EPS Next 2Y80.21%
EPS Next 3Y64.94%

4

5. Dividend

5.1 Amount

With a yearly dividend of 0.77%, ADN1 is not a good candidate for dividend investing.
Compared to an average industry Dividend Yield of 3.78, ADN1 has a dividend in line with its industry peers.
Compared to an average S&P500 Dividend Yield of 2.32, ADN1's dividend is way lower than the S&P500 average.
Industry RankSector Rank
Dividend Yield 0.77%

5.2 History

The dividend of ADN1 is nicely growing with an annual growth rate of 15.65%!
Dividend Growth(5Y)15.65%
Div Incr Years5
Div Non Decr Years6
ADN1.DE Yearly Dividends per shareADN1.DE Yearly Dividends per shareYearly Dividends per share 2019 2020 2021 2022 2023 2024 2025 0.2 0.4 0.6

5.3 Sustainability

31.75% of the earnings are spent on dividend by ADN1. This is a low number and sustainable payout ratio.
The dividend of ADN1 is growing, but earnings are growing more, so the dividend growth is sustainable.
DP31.75%
EPS Next 2Y80.21%
EPS Next 3Y64.94%
ADN1.DE Yearly Income VS Free CF VS DividendADN1.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
ADN1.DE Dividend Payout.ADN1.DE Dividend Payout, showing the Payout Ratio.ADN1.DE Dividend Payout.PayoutRetained Earnings

ADESSO SE

FRA:ADN1 (12/4/2025, 5:26:53 PM)

92

-0.2 (-0.22%)

Chartmill FA Rating
GICS IndustryGroupSoftware & Services
GICS IndustryIT Services
Earnings (Last)11-12 2025-11-12
Earnings (Next)03-27 2026-03-27/amc
Inst Owners19.2%
Inst Owner ChangeN/A
Ins Owners49.34%
Ins Owner ChangeN/A
Market Cap600.76M
Revenue(TTM)2.10B
Net Income(TTM)20.84M
Analysts81.54
Price Target126.63 (37.64%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0.77%
Yearly Dividend0.94
Dividend Growth(5Y)15.65%
DP31.75%
Div Incr Years5
Div Non Decr Years6
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.91%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0.11%
EPS NY rev (3m)-2.6%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.34%
Valuation
Industry RankSector Rank
PE 28.84
Fwd PE 15.53
P/S 0.29
P/FCF 12.85
P/OCF 7.73
P/B 3.14
P/tB 11.86
EV/EBITDA 6.78
EPS(TTM)3.19
EY3.47%
EPS(NY)5.92
Fwd EY6.44%
FCF(TTM)7.16
FCFY7.78%
OCF(TTM)11.9
OCFY12.93%
SpS322.11
BVpS29.27
TBVpS7.75
PEG (NY)0.27
PEG (5Y)N/A
Graham Number45.84
Profitability
Industry RankSector Rank
ROA 2.45%
ROE 10.9%
ROCE 11.91%
ROIC 5.23%
ROICexc 5.78%
ROICexgc 8.22%
OM 2.96%
PM (TTM) 0.99%
GM 85.3%
FCFM 2.22%
ROA(3y)1.93%
ROA(5y)3.99%
ROE(3y)6.49%
ROE(5y)13.12%
ROIC(3y)3.16%
ROIC(5y)4.51%
ROICexc(3y)4.06%
ROICexc(5y)6.01%
ROICexgc(3y)6.65%
ROICexgc(5y)10.11%
ROCE(3y)7.2%
ROCE(5y)10.26%
ROICexgc growth 3Y-20.34%
ROICexgc growth 5Y-12.01%
ROICexc growth 3Y-21.84%
ROICexc growth 5Y-11.01%
OM growth 3Y-30%
OM growth 5Y-15.03%
PM growth 3Y-55.28%
PM growth 5Y-30.54%
GM growth 3Y-0.02%
GM growth 5Y-0.7%
F-Score7
Asset Turnover2.47
Health
Industry RankSector Rank
Debt/Equity 1.6
Debt/FCF 7.88
Debt/EBITDA 2.26
Cap/Depr 42.37%
Cap/Sales 1.47%
Interest Coverage 5.03
Cash Conversion 57.42%
Profit Quality 224.33%
Current Ratio 1.3
Quick Ratio 1.3
Altman-Z 3.65
F-Score7
WACC10.29%
ROIC/WACC0.51
Cap/Depr(3y)52.06%
Cap/Depr(5y)49.68%
Cap/Sales(3y)2.64%
Cap/Sales(5y)2.54%
Profit Quality(3y)790.41%
Profit Quality(5y)538.39%
High Growth Momentum
Growth
EPS 1Y (TTM)200.98%
EPS 3Y-45.14%
EPS 5Y-15.02%
EPS Q2Q%9.8%
EPS Next Y105.03%
EPS Next 2Y80.21%
EPS Next 3Y64.94%
EPS Next 5Y39.75%
Revenue 1Y (TTM)12.6%
Revenue growth 3Y24.12%
Revenue growth 5Y23.6%
Sales Q2Q%13.44%
Revenue Next Year10.46%
Revenue Next 2Y10.44%
Revenue Next 3Y10.29%
Revenue Next 5Y10.61%
EBIT growth 1Y38.36%
EBIT growth 3Y-13.12%
EBIT growth 5Y5.01%
EBIT Next Year305.17%
EBIT Next 3Y80.92%
EBIT Next 5Y44.55%
FCF growth 1Y300.77%
FCF growth 3Y40.19%
FCF growth 5Y49.54%
OCF growth 1Y1010.67%
OCF growth 3Y32.14%
OCF growth 5Y37.69%

ADESSO SE / ADN1.DE FAQ

What is the ChartMill fundamental rating of ADESSO SE (ADN1.DE) stock?

ChartMill assigns a fundamental rating of 5 / 10 to ADN1.DE.


What is the valuation status of ADESSO SE (ADN1.DE) stock?

ChartMill assigns a valuation rating of 5 / 10 to ADESSO SE (ADN1.DE). This can be considered as Fairly Valued.


What is the profitability of ADN1 stock?

ADESSO SE (ADN1.DE) has a profitability rating of 4 / 10.


What is the valuation of ADESSO SE based on its PE and PB ratios?

The Price/Earnings (PE) ratio for ADESSO SE (ADN1.DE) is 28.84 and the Price/Book (PB) ratio is 3.14.


Is the dividend of ADESSO SE sustainable?

The dividend rating of ADESSO SE (ADN1.DE) is 4 / 10 and the dividend payout ratio is 31.75%.